Phase 2 N=131 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=6 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Adult T-Cell Lymphoma/Leukemia · Sezary Syndrome · Mycosis Fungoides
Primary: Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin 15 (IL-15) (rhIL-15) — 2 mcg/kg/day
Phase 2 N=33 Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Lymphoma
Primary: Response to Treatment — 0; 9 participants
Phase 2 N=28 Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
Metastatic Myxoid Liposarcoma · Metastatic Round Cell Liposarcoma · Metastatic Synovial Sarcoma
Primary: Overall Response Rate (ORR) — 6; 0 Participants
Phase 3 N=169 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
N/A N=298 Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Mycosis Fungoides
Primary: Treatment Responders Using Body Surface Area (BSA) at 12 Months — 44 Participants
Phase 1 N=26 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Phase 2 N=108 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Peripheral T Cell Lymphoma · Transformed Mycosis Fungoides
Primary: Overall Response Rate Assessed by Independent Review Committee Based on PET-CT — 32.4 percentage — p=0.051
Phase 2 N=36 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Non-Hodgkin Lymphoma (NHL) · Cutaneous Lymphoma · Cutaneous T-cell Lymphoma (CTCL)
Primary: Overall Response Rate (ORR) — 70; 56; 79; 100 percentage
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=77 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Peripheral T Cell Lymphoma · PTCL · Extranodal NK/T-cell Lymphoma
Primary: Overall Response Rate (ORR) — 31.8; 20.5; 45.5 Percentage of participants
Phase 2 N=5 Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants
Phase 3 N=131 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Primary Cutaneous Anaplastic Large Cell Lymphoma · Mycosis Fungoides · Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) — 54.7; 12.5 percentage of participants — p=<0.001
Phase 2 N=260 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Mycosis Fungoides
Primary: Ratio of Response Rates Based on CAILS — 76; 62 percentage of participants
Phase 2 N=9 Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
Mycosis Fungoides · Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
Primary: Proportion of Overall Cutaneous Responders at Their 9th or Final Cycle (Cutaneous Complete Response [CR], Cutaneous 90 Response [CR90] or Cutaneous Partial Response…